-
Posted by
Two Blokes Jun 24 -
Filed in
Stock
-
5 views
I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. LGND's business model supports sustainable revenue through royalties and partnerships with leading pharma firms.
